AgomAb Therapeutics NV’s (NASDAQ:AGMB) Quiet Period Will Expire on March 18th

AgomAb Therapeutics’ (NASDAQ:AGMB) quiet period will end on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its initial public offering on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AGMB. JPMorgan Chase & Co. started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target on the stock. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Morgan Stanley began coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 target price on the stock. Leerink Partners initiated coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 price target for the company. Finally, Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Price Performance

AGMB stock opened at $13.91 on Friday. AgomAb Therapeutics has a 12 month low of $12.66 and a 12 month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.